Marker Therapeutics, Inc.
AI Executive Summary
AI-powered analysis of 10-Q filing content
Marker Therapeutics continues burning cash at unsustainable levels with $3.2M quarterly loss and declining cash position. The company's runway appears limited with only $14.9M in cash remaining and quarterly burn rate exceeding $3M. A new $1M related party payable raises governance concerns about potential financial distress.
Red Flags Detected (6)
Cash decreased $1.15M in just 3 months from $16.1M to $14.9M
Quarterly net loss of $3.2M indicates unsustainable burn rate
New $1M related party payable appeared, suggesting potential cash flow issues
3 more red flags detected
Key Takeaways
Company has approximately 4-5 quarters of cash remaining at current burn rate
No revenue streams visible, entirely dependent on grant funding and cash reserves
2 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.